Drug Trial Radar · NCT06827431
The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
786
Actual
Start
Feb 21, 2025
Primary completion
Jul 14, 2026
Study completion Aug 20, 2026
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai Mental Health Center
- First posted
- Feb 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.
Conditions
- Major Depressive Disorder (MDD)
Interventions
AmmoxetineDrug
Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.
AmmoxetineDrug
Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Sertraline.
PlaceboDrug
Drug: Placebo placebo to Ammoxetine hydrochlorid and Sertraline.
SertralineDrug
Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8)Time frame: From baseline to Week 8
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University Sixth Hospital
Beijing, Beijing Municipality, China
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.